Kinase inhibitors: A new tool for the treatment of rheumatoid arthritis

被引：48

作者：

Chakravarty, Soumya D. ^{[1
,2
]}

Poulikakos, Poulikos I. ^{[3
,4
]}

Ivashkiv, Lionel B. ^{[1
,2
,5
]}

Salmon, Jane E. ^{[6
]}

Kalliolias, George D. ^{[1
,2
,7
]}

机构：

[1] Hosp Special Surg, Arthrit & Tissue Degenerat Program, New York, NY 10021 USA

[2] Hosp Special Surg, Dept Med, New York, NY 10021 USA

[3] Mt Sinai Sch Med, Tisch Canc Inst, Dept Oncol Sci, New York, NY 10029 USA

[4] Mt Sinai Sch Med, Tisch Canc Inst, Dept Dermatol, New York, NY 10029 USA

[5] Weill Cornell Grad Sch Med Sci, Grad Program Immunol & Microbial Pathogenesis, New York, NY 10021 USA

[6] Hosp Special Surg, Div Rheumatol, Weill Cornell Med Coll, New York, NY 10021 USA

[7] Weill Cornell Med Coll, Dept Med, New York, NY 10021 USA

来源：

CLINICAL IMMUNOLOGY | 2013年 / 148卷 / 01期

关键词：

Kinase inhibitors; Rheumatoid arthritis; TUMOR-NECROSIS-FACTOR; MODIFYING ANTIRHEUMATIC DRUGS; COLLAGEN-INDUCED ARTHRITIS; BRUTONS TYROSINE KINASE; PLACEBO-CONTROLLED TRIAL; N-TERMINAL KINASE; TOFACITINIB CP-690,550; INADEQUATE RESPONSE; INFLAMMATORY ARTHRITIS; PROTEIN-KINASE;

D O I：

10.1016/j.clim.2013.04.007

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

071005 [微生物学]; 100108 [医学免疫学];

摘要：

Despite aggressive immunosuppression with biologics and traditional DMARDs, achieving disease remission remains an unmet goal for most rheumatoid arthritis (RA) patients. In this context, there is a demand for novel treatment strategies, with kinase inhibitors expected to enrich the existing therapeutic armamentarium. In RA some kinases participate in the generation of pathogenic signaling cascades. Pharmacologic inhibition of kinases that mediate pathogenic signal transduction heralds a new era for RA therapeutics. Oral inhibitors of JAKs, Syk, PI3Ks, MAPKs and Btk are under development or in clinical trials in patients with RA. In this review, we discuss the scientific rationale for the use of kinase inhibitors in RA and summarize the experience from clinical trials. (C) 2013 Elsevier Inc. All rights reserved.

引用

页码：66 / 78

页数：13

共 117 条

[1]

The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling [J].

Ananieva, Olga ;

Darragh, Joanne ;

Johansen, Claus ;

Carr, Julia M. ;

McIlrath, Joanne ;

Park, Jin Mo ;

Wingate, Andrew ;

Monk, Claire E. ;

Toth, Rachel ;

Santos, Susana G. ;

Iversen, Lars ;

Arthur, J. Simon C. .

NATURE IMMUNOLOGY, 2008, 9 (09) :1028-1036

[2]

Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent [J].

Andraos, Rita ;

Qian, Zhiyan ;

Bonenfant, Debora ;

Rubert, Joelle ;

Vangrevelinghe, Eric ;

Scheufler, Clemens ;

Marque, Fanny ;

Regnier, Catherine H. ;

De Pover, Alain ;

Ryckelynck, Hugues ;

Bhagwat, Neha ;

Koppikar, Priya ;

Goel, Aviva ;

Wyder, Lorenza ;

Tavares, Gisele ;

Baffert, Fabienne ;

Pissot-Soldermann, Carole ;

Manley, Paul W. ;

Gaul, Christoph ;

Voshol, Hans ;

Levine, Ross L. ;

Sellers, William R. ;

Hofmann, Francesco ;

Radimerski, Thomas .

CANCER DISCOVERY, 2012, 2 (06) :512-523

[3]

[Anonymous], ANN RHEUM DIS S3

[4]

PI3 Kinase δ Is a Key Regulator of Synoviocyte Function in Rheumatoid Arthritis [J].

Bartok, Beatrix ;

Boyle, David L. ;

Liu, Yi ;

Ren, Pingda ;

Ball, Scott T. ;

Bugbee, William D. ;

Rommel, Christian ;

Firestein, Gary S. .

AMERICAN JOURNAL OF PATHOLOGY, 2012, 180 (05) :1906-1916

[5]

BELLI B, 2010, ARTHRITIS RHEUM, V62, pS112

[6]

The α-Isoform of p38 MAPK Specifically Regulates Arthritic Bone Loss [J].

Boehm, Christina ;

Hayer, Silvia ;

Kilian, Anita ;

Zaiss, Mario M. ;

Finger, Susann ;

Hess, Andreas ;

Engelke, Klaus ;

Kollias, George ;

Kroenke, Gerhard ;

Zwerina, Jochen ;

Schett, Georg ;

David, Jean-Pierre .

JOURNAL OF IMMUNOLOGY, 2009, 183 (09) :5938-5947

[7]

Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes [J].

Boisson-Dupuis, Stephanie ;

Kong, Xiao-Fei ;

Okada, Satoshi ;

Cypowyj, Sophie ;

Puel, Anne ;

Abel, Laurent ;

Casanova, Jean-Laurent .

CURRENT OPINION IN IMMUNOLOGY, 2012, 24 (04) :364-378

[8]

R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation [J].

Braselmann, Sylvia ;

Taylor, Vanessa ;

Zhao, Haoran ;

Wang, Su ;

Sylvain, Catherine ;

Baluom, Muhammad ;

Qu, Kunbin ;

Herlaar, Ellen ;

Lau, Angela ;

Young, Chi ;

Wong, Brian R. ;

Lovell, Scott ;

Sun, Thomas ;

Park, Gary ;

Argade, Ankush ;

Jurcevic, Stipo ;

Pine, Polly ;

Singh, Rajinder ;

Grossbard, Elliott B. ;

Payan, Donald G. ;

Masuda, Esteban S. .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 319 (03) :998-1008

[9]

Why does chronic inflammation persist: An unexpected role for fibroblasts [J].

Buckley, Christopher D. .

IMMUNOLOGY LETTERS, 2011, 138 (01) :12-14

[10]

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial [J].

Burmester, Gerd R. ;

Blanco, Ricardo ;

Charles-Schoeman, Christina ;

Wollenhaupt, Juergen ;

Zerbini, Cristiano ;

Benda, Birgitta ;

Gruben, David ;

Wallenstein, Gene ;

Krishnaswami, Sriram ;

Zwillich, Samuel H. ;

Koncz, Tamas ;

Soma, Koshika ;

Bradley, John ;

Mebus, Charles .

LANCET, 2013, 381 (9865) :451-460

← 1 2 3 4 5 6 7 8 9 10 →